Galapagos NV
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
07 mrt 2014 - 07:30
Statutaire naam
Galapagos NV
Titel
Galapagos reports 2013 financial results
Bericht
Maturing pipeline supported by very strong balance sheet
· Group revenues €160 M (+4% over '12), equal to guidance
· Group net loss €8.1 M ('12: €5.7 M)
· Year-end cash €141.5 M, excluding €6.0 M in milestone receivables for 2013 revenues and also excluding €33 M under the CIR program of the French government
· Expansions of GLPG0634 franchise with AbbVie for Phase 2 studies in RA & Crohn's disease
· Major collaboration with AbbVie signed in cystic fibrosis, nomination of candidate potentiator GLPG1837
Datum laatste update: 20 december 2025